Document is current
Any future updates will be listed below
-
Authors
Kangas, Brian D.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (R01-MH136052)
National Institute on Drug Abuse (R01-DA047575)
- License Information
-
More Information
Article History
Received: 15 May 2025
Accepted: 28 August 2025
First Online: 19 September 2025
Compliance with Ethical Standards
:
: During the past 3 years, BDK has received sponsored research agreements from BlackThorn Therapeutics, Compass Pathways, Delix Therapeutics, Engrail Therapeutics, Neurocrine Biosciences, and Takeda Pharmaceuticals. No funding from these entities was used to support the current work.
